TG Therapeutics, Inc.
TGTX
$30.63
-$1.04-3.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 92.79% | 92.13% | 90.40% | 146.04% | -49.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 92.79% | 92.13% | 90.40% | 146.04% | -49.41% |
| Cost of Revenue | 200.75% | 128.06% | 185.63% | 96.07% | 166.20% |
| Gross Profit | 79.26% | 87.55% | 81.47% | 156.90% | -54.08% |
| SG&A Expenses | 51.01% | 43.30% | 45.55% | 25.07% | 28.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.24% | 64.43% | 54.29% | 38.58% | 40.00% |
| Operating Income | 136.17% | 295.22% | 193.01% | 339.88% | -89.17% |
| Income Before Tax | 507.05% | 371.99% | 151.21% | 281.47% | -96.25% |
| Income Tax Expenses | -94,168.56% | 933.23% | 1,306.90% | 444.10% | -- |
| Earnings from Continuing Operations | 9,974.61% | 309.75% | 147.26% | 261.84% | -96.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9,974.61% | 309.75% | 147.26% | 261.84% | -96.59% |
| EBIT | 136.17% | 295.22% | 193.01% | 339.88% | -89.17% |
| EBITDA | 136.09% | 294.52% | 193.39% | 340.68% | -89.16% |
| EPS Basic | 9,967.79% | 304.42% | 147.13% | 259.48% | -96.65% |
| Normalized Basic EPS | 505.43% | 365.37% | 151.10% | 278.63% | -96.31% |
| EPS Diluted | 12,050.00% | 325.00% | 140.98% | 248.76% | -97.26% |
| Normalized Diluted EPS | 506.02% | 362.65% | 146.05% | 261.99% | -96.37% |
| Average Basic Shares Outstanding | 0.22% | 1.39% | 0.32% | 1.50% | 1.56% |
| Average Diluted Shares Outstanding | 0.18% | 1.97% | 11.33% | 11.99% | 3.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |